Trevi Therapeutics (TRVI) | Stock Overview & Key Data
Trevi Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $8.01
High: $9.70
on September 12, 2025
52 Week Range
Low: $2.36
High: $9.92
on December 11, 2024
on September 11, 2025
All-Time High: $10.62 on June 3, 2019
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.0B
EPS
-0.42
P/E Ratio (TTM)
-17.55
Forward P/E
-17.19
P/B Ratio
5.06
PEG Ratio
0.70
Div. Yield
N/A
ROE
-35.74%
Beta
0.718
Debt to Equity
0.45
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-22.83%
Return on Equity (TTM)
-35.74%
EBITDA
$-51.4M
Net Income (TTM)
$-47.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Trevi Therapeutics TRVI | 1.00B Small-cap | 17.69% | 12.55% | 33.71% | 30.95% | 89.22% | 144.81% | 153.07% | 105.22% |
| Vertex VRTX | 101.15B Large-cap | -0.40% | 1.74% | -14.24% | -20.36% | -2.77% | -18.72% | 36.18% | 48.66% |
| Alnylam ALNY | 61.07B Large-cap | 3.07% | 8.36% | 52.92% | 92.18% | 99.42% | 75.61% | 118.70% | 252.21% |
| Adaptive ADPT | 1.92B Small-cap | -1.87% | -0.39% | 21.13% | 65.49% | 103.72% | 173.54% | 65.27% | -72.79% |
| Dyne Therapeutics DYN | 1.87B Small-cap | -7.52% | 13.17% | -9.06% | 6.39% | -48.35% | -61.39% | -3.66% | -42.32% |
| Harmony Biosciences HRMY | 1.86B Small-cap | -10.00% | -8.68% | -2.82% | -3.60% | -7.01% | -16.76% | -26.12% | -3.60% |
Ownership & Short Interest
Insider Ownership
0.72%
Institutional Ownership
92.78%
Shares Short
12M
Short Ratio
6.36
Short % of Shares Outstanding
11.12%
Average 10-Day Volume
3M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TRVI's 52-week high and low?
- In the last 52 weeks, Trevi Therapeutics reached a high of $9.92 (on September 11, 2025) and a low of $2.36 (on December 11, 2024).
- What is the market cap and P/E ratio for TRVI?
- Curious about Trevi Therapeutics's size and valuation? Its market capitalization stands at 1.00B. When it comes to valuation, the P/E ratio (trailing twelve months) is -17.55, and the forward P/E (looking ahead) is -17.19.
- Does TRVI pay dividends? If so, what's the yield?
- As for dividends, Trevi Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Trevi Therapeutics's main competitors or similar companies to consider before investing?
When looking at Trevi Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.15B Healthcare Biotechnology -18.72% 36.18% Alnylam
ALNY61.07B Healthcare Biotechnology 75.61% 118.70% Adaptive
ADPT1.92B Healthcare Biotechnology 173.54% 65.27% Dyne Therapeutics
DYN1.87B Healthcare Biotechnology -61.39% -3.66% Harmony Biosciences
HRMY1.86B Healthcare Biotechnology -16.76% -26.12% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Trevi Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Trevi Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -35.74%, the Debt to Equity ratio from the most recent quarter is 0.45, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for TRVI?
- Looking at Trevi Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of TRVI stock is held by insiders and institutions?
- Wondering who owns Trevi Therapeutics stock? Company insiders (like executives and directors) hold about 0.72% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 92.78%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.